What is the 13F Pro Quality Score for TIL?

13F Pro ranks Instil Bio, Inc. (TIL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TIL's current score at https://13fpro.ai/research/TIL (free sign-up required for the full ranking).

Which hedge funds own the most TIL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TIL include Curative Ventures V, BML Capital Management,, CPMG. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TIL as soon as new 13F filings post.

Where does 13F Pro source TIL data?

All Instil Bio, Inc. fundamentals and ownership data come directly from SEC EDGAR. Instil Bio, Inc. files with the SEC under CIK 1789769. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TIL in?

Instil Bio, Inc. (TIL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TIL research updated on 13F Pro?

TIL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Instil Bio, Inc.(TIL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1789769 TIL stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 32 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

TIL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Instil Bio, Inc. (TIL), a Healthcare sector company. TIL is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 32 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), Instil Bio, Inc. reports net income of $-4.2M, free cash flow of $-1.3M. Top institutional holders of TIL by reported 13-F value include Curative Ventures V, BML Capital Management,, CPMG, based on the most recent SEC filings. TIL trades on the Nasdaq exchange and files with the SEC under CIK 1789769. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TIL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Instil Bio, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-4.2M

Free Cash Flow

Q1 2026

$-1.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+110.2% YoY

$9.0MFY 2025

FY22 —FY23 $0.00FY24 $4.3MFY25 $9.0M

Net Income

+3.7% YoY

$-71.4MFY 2025

FY22 $-223.2MFY23 $-156.1MFY24 $-74.1MFY25 $-71.4M

Operating Income

-6.9% YoY

$-78.6MFY 2025

FY22 $-226.5MFY23 $-159.2MFY24 $-73.5MFY25 $-78.6M

EPS (Diluted)

+6.1% YoY

$-10.70FY 2025

FY22 $-34.46FY23 $-24.00FY24 $-11.39FY25 $-10.70

Total Assets

-22.8% YoY

$203.5MFY 2025

FY22 $482.1MFY23 $325.6MFY24 $263.6MFY25 $203.5M

Op. Cash Flow

+34.3% YoY

$-36.6MFY 2025

FY22 $-180.2MFY23 $-82.0MFY24 $-55.7MFY25 $-36.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$9.0M +110.2%	$4.3M	$0.00	—	$138.0K	—
Net Income	$-71.4M +3.7%	$-74.1M +52.5%	$-156.1M +30.1%	$-223.2M -491.4%	$-37.7M	—
Operating Income	$-78.6M -6.9%	$-73.5M +53.8%	$-159.2M +29.7%	$-226.5M -573.1%	$-33.6M	—
EPS (Diluted)	$-10.70 +6.1%	$-11.39 +52.5%	$-24.00 +30.4%	$-34.46 -1360.2%	$-2.36	—
Total Assets	$203.5M -22.8%	$263.6M -19.1%	$325.6M -32.5%	$482.1M +51.1%	$319.0M	—
Operating Cash Flow	$-36.6M +34.3%	$-55.7M +32.1%	$-82.0M +54.5%	$-180.2M -508.3%	$-29.6M	—

AI Insight: TIL Financial Trends

Net losses narrowing sharply—from $28M in Q1 2025 to $4M in Q1 2026—while equity base stabilizes around $111M.

• Net loss contracted 86% over four quarters: $28M (Q1 2025) to $4M (Q1 2026); operating loss similarly compressed 77%.

• Operating cash flow improved materially: $4M negative in Q1 2025 versus $1M negative in Q1 2026, approaching break-even.

• Equity declined 43% from $195M (Q2 2024) to $111M (Q1 2026) as cumulative losses consumed capital; now stabilizing.

⚠ No revenue visible across entire 8-quarter period—company remains pre-commercial; cash burn trajectory critical to viability.

⚠ Equity depletion accelerated in early 2025 ($195M to $132M in 12 months); burn-rate improvement must sustain or raise needed.

AI Insight: TIL Ratio Trends

Instil Bio's return metrics are steadily improving but remain deeply negative, signaling ongoing losses narrowing from a trough in Q1 2025.

• ROE improved from -77.8% in Q1 2025 to -15.2% in Q1 2026, a 62.6pp swing; ROIC recovered from -84.4% to -25.3% over same period.

• ROA trajectory shows consistent improvement: -47.5% (Q1 2025) → -8.4% (Q1 2026), indicating asset efficiency gains.

⚠ All return metrics remain deeply negative; company still unprofitable. Absolute profitability inflection not yet visible.

⚠ TTM ROE of -42.8% and ROIC of -49.7% lag latest quarter, suggesting recent improvement may be offset by earlier losses.

Get alerted when TIL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Instil Bio, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TIL

Curative Ventures V LLC
$15.6M1,899,004 sh
BML Capital Management, LLC
$5.3M645,600 sh
CPMG Inc
$3.4M410,922 sh
Vivo Capital, LLC
$2.4M292,743 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.4M174,583 sh
Kalehua Capital Management LLC
$1.2M139,849 sh
MILLENNIUM MANAGEMENT LLC
$1.1M132,946 sh
RENAISSANCE TECHNOLOGIES LLC
$487.0K59,100 sh
BlackRock, Inc.
$428.6K52,018 sh
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$412.0K50,000 sh

Fund	Value	Shares
Curative Ventures V LLC	$15.6M	1,899,004
BML Capital Management, LLC	$5.3M	645,600
CPMG Inc	$3.4M	410,922
Vivo Capital, LLC	$2.4M	292,743
VANGUARD CAPITAL MANAGEMENT LLC	$1.4M	174,583
Kalehua Capital Management LLC	$1.2M	139,849
MILLENNIUM MANAGEMENT LLC	$1.1M	132,946
RENAISSANCE TECHNOLOGIES LLC	$487.0K	59,100
BlackRock, Inc.	$428.6K	52,018
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.	$412.0K	50,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TIL on your watchlist

Track score changes the day Instil Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TIL a good stock to buy?

13F Pro's AI-powered analysis of Instil Bio, Inc. (TIL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TIL are available on the TIL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TIL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TIL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Instil Bio, Inc.'s investment landscape.